Encapsulated adipose-derived stem cells, methods for preparation and theraputic use

{
  "publication_number": "US9938501B2",
  "country": "US",
  "kind": "B2",
  "title": "Encapsulated adipose-derived stem cells, methods for preparation and theraputic use",
  "abstract": "A therapeutic composition comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in a three-dimensional biocompatible gel matrix, and methods, and systems for preparing and using encapsulated adipose-derived mesenchymal stem cells. Hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The gel matrix allows the release of cellular factors from the encapsulated stem cells to surrounding tissues to achieve desired therapeutic results.",
  "claims": [
    "1. A therapeutic composition comprising: an injectable suspension of a plurality of microbeads of a biocompatible fibrin hydrogel; wherein each microbead comprises from about 2,000 to about 10,000 adipose-derived stem cells encapsulated within the hydrogel; wherein the microbeads are adapted to release cellular factors from the stem cells to a target tissue of the patient into which the microbeads are introduced.",
    "2. The therapeutic composition of claim 1, wherein the microbeads have a volume between 10 and 50 μL.",
    "3. The therapeutic composition of claim 1, wherein the microbeads comprise about 200 stem cells per microliter.",
    "4. The therapeutic composition of claim 1, wherein the microbeads are adapted to protect the stem cells from mechanical and chemical stress when introduced to the patient.",
    "5. The therapeutic composition of claim 1, wherein the microbeads are adapted to maintain the stem cells in an undifferentiated condition for a period of three to fourteen days.",
    "6. The therapeutic composition of claim 1, wherein the stem cells are autologous stem cells.",
    "7. The therapeutic composition of claim 1, wherein the stem cells are allogeneic stem cells.",
    "8. The therapeutic composition of claim 1, wherein the plurality of microbeads are frozen microbeads.",
    "9. The therapeutic composition of claim 1, wherein the plurality of microbeads are thawed microbeads adapted to be resuspended in a biocompatible fluid before injection into a patient.",
    "10. The therapeutic composition of claim 1, wherein the stem cells are mesenchymal stem cells.",
    "11. The therapeutic composition of claim 1, wherein the stem cells are uncultured stem cells.",
    "12. The therapeutic composition of claim 1, wherein the microbeads are formed from about 10 mg/mL fibrinogen in the presence of about 50 mg/mL thrombin."
  ],
  "description_excerpt": "This application claims priority to U.S. Provisional Patent Application 61/368,513, entitled “Methods And Compositions Using Therapeutic Stem Cells” filed Jul. 28, 2010; U.S. Provisional Patent Application 61/368,528, entitled “Production Of Therapeutic Cells” filed Jul. 28, 2010, both of which are incorporated herein by reference.\n\nThis invention relates generally to therapeutic compositions including stem cells derived from adipose tissue, including systems for preparing, delivering and utilizing such therapeutic compositions.\n\nRegenerative medicine can be defined as harnessing the body's regenerative mechanisms in a clinically targeted manner, using them in ways that are not part of the normal healing mechanism or by artificially amplifying normal mechanisms. Stem cells are pluripotent or multipotent cells with the potential to differentiate into a variety of other cell types, which perform one or more specific functions and have the ability to self-renew. It has been found that stem cells from a variety of sources can be used for multiple therapeutic or prophylactic purposes. For example, hematopoetic stem cells (HSCs) derived from bone marrow are multipotent stem cells that can give rise to cell types from the myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells), and lymphoid lineages (T-cells, B-cells, NK-cells).",
  "cpc": [
    "C12N 5/0655",
    "A61K 2035/126",
    "A61K 35/28",
    "A61K 9/0019",
    "A61K 9/1658",
    "A61L 27/3834",
    "A61L 27/52",
    "A61P 19/02",
    "A61P 19/08",
    "A61P 43/00",
    "C12N 2533/56",
    "C12N 5/0667"
  ],
  "ipc": [
    "A61K 35/12",
    "A61P 19/02",
    "A61P 43/00",
    "A61K 35/28",
    "A61K 9/16",
    "A61K 35/32",
    "A61K 9/00",
    "A61L 27/38",
    "A61L 27/52",
    "C12N 5/077",
    "C12N 5/0775"
  ],
  "assignees": [
    "JOINTECHLABS Inc"
  ],
  "inventors": [
    "Nathan Katz",
    "Felix Pustilnik"
  ],
  "filing_date": "2011-07-28",
  "publication_date": "2018-04-10",
  "grant_date": "2018-04-10",
  "priority_date": "2010-07-28",
  "application_number": "US-201113193468-A",
  "family_id": "45526981",
  "cited_by_count": 3,
  "citations": [
    "US5486359A",
    "US20030012734A1",
    "US6150505A",
    "US20020110544A1",
    "US20040157951A1",
    "US20020155096A1",
    "US20030211083A1",
    "US20050260175A1",
    "US20060233854A1",
    "US20080044900A1",
    "US20080031858A1",
    "US20100003328A1",
    "US20090269406A1",
    "US20130039990A1",
    "US20120087983A1"
  ]
}